The Biased GLP-1 Signal: Ecnoglutide’s 35% Edge Over Semaglutide Is the Opening Shot in Obesity’s Next Competitive War
Sciwind's ecnoglutide beat semaglutide by 35% on weight loss in a head-to-head trial—and it signals a coming wave of...
Obesity/GLP-1
Novo Nordisk’s Zenagamtide Isn’t Chasing Ozempic — It’s Trying to Make Tirzepatide Obsolete
Novo Nordisk's zenagamtide hit 14.6% weight loss and 89.1% A1C control in Phase 2. Here's what the ADA 2026...
The Triple Threat: Incretin Multi-Agonists Are About to Redraw the $77B Obesity Map
Nature Reviews flags incretin multi-agonist reversal of obesity and diabetes — Lilly's retatrutide Phase 3 data signals the GLP-1...
Novo Nordisk’s 20.7% Weight Loss Number Changes the GLP-1 Rulebook
Novo Nordisk's Wegovy 7.2 mg CHMP approval delivers 20.7% mean weight loss — rewriting competitive benchmarks for Eli Lilly's...
The GLP-1 Wars Are Over — The Incretin Platform Wars Have Begun
Orforglipron's 72-week Phase 3 data, SURMOUNT-5's head-to-head verdict, and Roche's oral small molecule push signal a $87B market restructuring...
Lilly’s Oral Pivot: Foundayo’s Maintenance Data Isn’t a Scientific Win — It’s a Market Access Weapon
Lilly's ATTAIN-MAINTAIN trial shows Foundayo maintains weight loss after injectable GLP-1s — a $42B market's access problem just found...
Novo Nordisk’s Patent Cliff Isn’t Coming — It’s Already Here, and the Pricing Model Breaks on Impact
Semaglutide's patent expiration isn't a future problem for GLP-1 manufacturers — it's an active restructuring of the global obesity...
Novo Nordisk’s Hims & Hers Deal Isn’t a Distribution Play — It’s a Controlled Burn of Its Own Pricing Floor
Hims & Hers posted its best weekly stock gain after announcing a deal with Novo Nordisk, and Wall Street...